E-cigarette or Vaping-Associated Lung Injury (EVALI) complicated by invasive aspergillosis

Medicine & Life Sciences

• Vaping 100%
• Electronic Nicotine Delivery Systems 96%
• Aspergillosis 81%
• Lung Injury 72%
• Cannabis 51%
• Dronabinol 36%
• Invasive Pulmonary Aspergillosis 28%
• Empyema 24%
• Tobacco Products 18%
• Biological Evolution 15%
• Necrotizing Pneumonia 15%
• galactomannan 14%
• Cefuroxime 12%
• Amoxicillin-Potassium Clavulanate Combination 12%
• Bacterial Pneumonia 12%
• Voriconazole 12%
• Belgium 11%
• Aspergillus 11%
• Bronchoalveolar Lavage Fluid 10%
• Immunocompromised Host 10%
• Pleural Effusion 10%
• Centers for Disease Control and Prevention (U.S.) 10%
• Mycoses 9%
• Cough 9%
• Bacterial Infections 9%
• Fungi 8%
• Chronic Obstructive Pulmonary Disease 8%
• Disease Outbreaks 8%
• Tertiary Care Centers 8%
• Smokers 8%
• Therapeutics 7%
• Pneumonia 7%
• Yeasts 7%
• Hospital Emergency Service 7%
• Differential Diagnosis 7%
• Hospitalization 7%
• Thorax 6%
• Anti-Bacterial Agents 6%